Galanin receptor 2-neuropeptide Y Y1 receptor interactions in the amygdala lead to increased anxiolytic actions.
Galanin (GAL) and neuropeptide Y (NPY) are neuropeptides involved in behaviors associated with anxiety. Both neuropeptides interact in several central functions. However, the potential behavioral and cellular interactions between them in anxiety are unknown. GAL was found to act through GAL receptor 2 (GALR2) to enhance NPYY1 receptor (NPYY1R)-mediated anxiolytic behaviors in rats. Using receptor autoradiography, c-Fos expression and in situ proximity ligation assay, the medial paracapsular intercalated nuclei of the amygdala were determined to be a key area in the interaction probably involving the formation of GALR2/NPYY1R heteroreceptor complexes. In cell cultures costimulation of GALR2 and NPYY1R induced changes in the functions of these receptors. The changes involved a potentiation of the decrease in the phosphorylation of CREB induced by NPYY1R and a delay in the internalization of NPYY1R. These results indicate that GALR2/NPYY1R interactions can provide a novel integrative amygdaloid mechanism in anxiety.
Universidad de Málaga, Instituto de Investigación Biomédica, Facultad de Medicina, Málaga, Spain.
Manuel
M
Narváez
Carmelo
C
Millón
Dasiel
D
Borroto-Escuela
Antonio
A
Flores-Burgess
Luis
L
Santín
Concepción
C
Parrado
Belén
B
Gago
Araceli
A
Puigcerver
Kjell
K
Fuxe
José Angel
JA
Narváez
Zaida
Z
Díaz-Cabiale
D000679:Amygdala / Q000187:drug effects / Q000378:metabolism*; D000818:Animals; D001345:Autoradiography; D001920:Bradykinin / Q000031:analogs & derivatives / Q000494:pharmacology; D004333:Drug Administration Routes; D004347:Drug Interactions; D005106:Exploratory Behavior / Q000187:drug effects; D019004:Galanin / Q000494:pharmacology / Q000031:analogs & derivatives; D049452:Green Fluorescent Proteins / Q000235:genetics / Q000378:metabolism; D057809:HEK293 Cells; D006801:Humans; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D009478:Neuropeptide Y / Q000031:analogs & derivatives / Q000494:pharmacology; D010446:Peptide Fragments / Q000494:pharmacology; D010455:Peptides / Q000494:pharmacology; D011485:Protein Binding / Q000187:drug effects; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D044092:Receptor, Galanin, Type 2 / Q000235:genetics / Q000378:metabolism*; D017476:Receptors, Neuropeptide Y / Q000235:genetics / Q000378:metabolism*; D018709:Statistics, Nonparametric; D014162:Transfection
C000614145:M617 peptide; C000603588:M871 peptide; D009478:Neuropeptide Y; D010446:Peptide Fragments; D010455:Peptides; D016760:Proto-Oncogene Proteins c-fos; D044092:Receptor, Galanin, Type 2; D017476:Receptors, Neuropeptide Y; C485184:enhanced green fluorescent protein; C097212:neuropeptide Y-Y1 receptor; C062259:neuropeptide Y, Leu(31)-Pro(34)-; D049452:Green Fluorescent Proteins; D019004:Galanin; D001920:Bradykinin